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Superagonistic activity of these antibodies was shown to be 
as a result of their binding to C″D loop of CD28 receptor 
in contrast to other CD28 antibodies which bind to a site 
close to binding site of natural ligands. Since activation 
of regulatory T cells can be useful for the treatment of 
a variety of autoimmune diseases and cancer, they were 
investigated for their therapeutic potential in different 
animal models for their superagonist activity.[3] One such 
antibody TGN1412 by TeGenero underwent rigorous 
preclinical investigation prior to its approval for clinical 
trials. TGN1412 could cause ex vivo expansion of T cells 
in the absence of additional stimuli from T-cell receptor. 
In preclinical studies, well-tolerated expansion of T cells 
was observed without any measurable proinflammatory 
reaction. Moreover, TGN1412 also demonstrated its 
therapeutic potential for use in autoimmune disease 
because of its capability of activating regulatory T cells. 
Thus, depending upon the condition of the immune system 
INTRODUCTION
CD28 superagonist antibodies can cause activation and 
proliferation of regulatory T cells regardless of signal 
received by T-cell receptor. Regulatory CD4+CD25+ T 
cells play an important role in prevention of autoimmune 
diseases.[1] Activation of regulatory T cells by antigens is 
controlled by co-stimulatory signal from antigen presenting 
cells, mainly dendritic cells (DC) where antigen is presented 
by MHC complex of DC to T cells via T-cell receptor. 
This along with co-stimulation of CD28 receptor by CD80 
or CD86 ligand on DC is required for T-cell activation.  [2] 
In vitro it was possible to stimulate T cells by the use 
of combination of antibodies against T-cell receptor 
and CD28 receptor. Monoclonal anti-CD28 antibody 
such as TGN1412 was capable of activating T cells by 
binding to CD28 receptor irrespective of T-cell receptor 
activation and hence it was termed as a CD28 superagonist. 
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ABSTRACT
After a drug is confirmed as safe and efficacious in preclinical studies, it is tested in healthy human volunteers for 
first in man trials. In 2006, a phase I clinical study was conducted for a CD28 superagonist antibody TGN1412 in 
six human volunteers. After very first infusion of a dose 500 times smaller than that found safe in animal studies, 
all six human volunteers faced life-threatening conditions involving multiorgan failure for which they were moved 
to intensive care unit. After this particular incident, a lot was changed over how first in man trials are approved 
by regulatory authorities and the way clinical trials are conducted. This review primarily deals with preclinical 
studies conducted by TeGenero, results of which encouraged them to test the antibody on human subjects, 
reasons why this drug failed in human trial and aftermath of this drug trial. In addition, another drug—Fialuridine 
which failed in phase 2 clinical trial leading to death of five human subjects is briefly reviewed.
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TGN1412 was thought to be useful for disease related to 
low numbers of activated T such as B-cell lymphoma or 
for treatment of autoimmune diseases such as rhematoid 
arthritis. When this antibody was tested in humans, it was 
immediately withdrawn from phase 1 clinical trials and 
volunteers had to be taken to intensive care unit 8 h after 
drug infusion due to multiorgan failure.[4]
DEVELOPMENT OF TGN1412
After identification of CD28 antibodies capable of 
activating T cells along with signal from T-cell receptors, 
studies were conducted to evaluate T-cell activation 
potential of these CD28 antibodies. Large number of 
mouse hybridomas were isolated and investigated for 
functional activity through CD28. It was found that one 
category of these antibodies was capable of activating T 
cells irrespective of signal received from T-cell receptor. 
They were named as CD28 superagonists. These antibodies 
did not differ in antibody class or the binding avidity for 
the CD28 receptor but differed in the epitope-binding site. 
Conventional CD28 antibody-binding site was at the top 
of CD28 molecule where the natural CD28 ligands bind, 
while the CD28 superagonist required an intact CD28 C″D 
loop for its binding.[2] Toward further development of 
this class of antibodies, TeGenero started with screening 
of several mouse monoclonal CD28 superagonist 
antibodies. From these studies, TGN1412, a genetically 
engineered humanized anti-CD28 antibody was produced 
by transferring complement-determining regions from 
variable regions of heavy and light chains of monoclonal 
anti-mouse CD28 antibody 5.11A1 into human heavy 
and light chain variable antibody construct. Huminized 
heavy and light variable regions were then combined 
with IgG4γ and κ chain coding human gene. A mouse 
antibody used in humans may have toxicity problems 
related to immunogenicity and problems related to effective 
functioning of antibody. To avoid these problems, the 
above humanized antibody TGN1412 was constructed.[2]
IN VITRO EVALUATIONS OF TGN1412 IN HUMAN 
AND NON-HUMAN CELLS
Specificity of TGN1412 to CD28 was evaluated by flow 
cytometry and Biacore analysis. These assays showed 
specificity of TGN1412 for CD28 receptor and that 
TGN1412 did not cross react with other closely related 
molecular targets such as Cytotoxic T-lymphocyte-
antigen-4 and inducible co-stimulator. In vitro studies for 
cross reactivity of TGN1412 with CD28 expressed on T 
cells of rodents and non-human primates revealed that 
TGN1412 had low-binding affinity for rodent CD 28 
whereas the same was high in case of T cells from for CD 
28 to T cells derived from cynomolgus monkey and rhesus 
monkey. Determination of sequence homology of C″D 
loop of CD28 of humans and rhesus revealed difference 
of one amino acid while that in marmoset monkey revealed 
difference of two out of six amino acids. In case of 
rodents, the C″D loop sequence homology with humans 
was very low. When incubated with different subsets of 
T cells obtained from healthy donars, only TGN1412 but 
not conventional CD28 antibody was able to cause rapid 
proliferation of T cells in the absence of stimuli from 
T-cell receptor. These results showed that TGN1412 had 
superagonistic activity for T cells obtained from healthy 
donars and that they could specifically react with CD28 
receptor having sequence homology with human CD28 
receptor.[2]
IN VIVO STUDIES
Prior to use of TGN1412 different antibody variants 
were used for preclinical studies. All these studies 
demonstrated that these superagonist are safe and 
efficacious (Investigation brochure, 2005). These 
encouraging results demonstrated high possibility for the 
use of this superagonist for the treatment of different 
T-cell deficiency syndromes like auto-immune diseases 
and B-cell lymphoma. To further evaluate its efficacy, 
humanized antibody as described above was engineered 
from 5.11A1 mouse human CD28 antibody. Selection of 
proper non-human primate model was an important issue 
for testing further safety and efficacy of this antibody. 
Toward this end, cynomolgus and rhesus monkeys were 
chosen because the CD28 receptor in these species and 
humans have similar affinity for TGN1412[5] because of 
100% sequence homology of extracellular domain of 
CD28 receptor.[5] Moreover, Fc receptors and their motifs 
responsible for signal transduction in these species are 
highly conserved in human species hence similar antibody 
affinities and response can be expected. On the basis of 
this hypothesis, it was decided that results obtained from 
pharmacokinetic and pharmacodynamic studies in these 
closely related species would most closely predict fate of 
drug response when tested in humans. A repeat dose study 
for toxicokinetic evaluation of TGN1412 was conducted. 
In this study, doses ranging from 5 to 50 mg/kg were 
administered. Plasma half-life of TGN1412 was found to 
be 8 h which was as expected for a large protein molecule 
like an antibody. Despite four increasing repeated doses of 
TGN1412 resulting in four plasma peaks concentrations 
of TGN1412, only one peak for increase in T-cell number 
TGN1412334   J Young Pharm Vol 2 / No 3
was observed. This was because extent of expansion of 
T cells by TGN1412 is highly dependent on availability 
of T cells and saturation kinetics of CD28 co-stimulator 
receptor. After these studies, toxicological studies using 
rhesus and cynomolgus monkeys were conducted. Rodent 
species were not considered appropriate because of 
difference in binding affinities of TGN1412 at the C″D 
loop of CD28 receptor. A repeat dose pilot study was 
conducted in cynomolgus and rhesus monkey. In this study, 
an increasing dose of TGN1412 starting from 5 to 50 mg/
mL was administered. Dose as high as 50 mg/mL was well 
tolerated and no adverse reactions such as systemic immune 
system disregulation or hypersensitive reactions were 
observed. In addition, no signs of toxicity were observed 
in any of the physiological systems including cardiovascular 
system, respiratory system, or central nervous system. On 
the basis of these results, no observed drug effect level 
was considered to be 50 mg/kg. For additional toxicity 
studies, rat anti-CD28 antibody jj316 or TGN1112 (IgI 
variant of TGN1412) were used for toxicological studies 
in relevant species. Expected pharmacodynamic effect of 
TGN1412, that is elevation in levels of CD4+ and CD8+ 
was observed after 13 days of initial dosing. Levels of 
IL-2, IL-6, and IL-5 were moderately increased in serum 
in animals treated with TGN1412. However, from these 
studies there was no indication or sign of any clinical 
manifestations of first dose cytokine release syndrome in 
any of the CD28 superagonist antibody-treated animals 
since elevation of cytokine levels was observed only for 
a week at 5 mg/kg dose of TGN1412. In addition, there 
was no signal from any of the animals treated with any 
dose of superagonist indicating symptoms of anaphylactic 
shock or development of autoimmune disease, or systemic 
immune suppression. In addition to these studies, tissue 
cross-reactivity studies were performed where distribution 
of lymphocytes was observed by lymphocyte staining. 
These studies revealed a consistent tissue staining in 
lymphoid tissue as expected demonstrating target-tissue 
specificity of CD28 superagonist. In addition, studies for 
immunogenicity of TGN1412 were performed on primate 
model. Anti-TGN1412 antibody titers were observed in all 
animals, which were thought to be as a consequence of 
the humanized antibody being used in primate model.[1–5] 
Hence, TGN1412 proved to be safe and efficacious and 
passed a variety of conventional preclinical safety tests such 
as in vitro tests on human white blood cells and preclinical 
tests in non-human primates which bagged TeGenero 
approvals from UK and German regulatory authorities 
for first in man phase 1 trial for this new therapeutic agent 
with an unusual mode of action.[6] 
CLINICAL DEVELOPMENT OF TGN1412
After getting approval from regulatory authorities, phase 1 
trials were conducted. The main aim was to establish safe 
human dose which can be further be used for subsequent 
drug trials. For this purpose, it was decided to conduct 
the trials on healthy human volunteers because disease 
free subjects have comparable CD28 receptors as in 
case of rhematioid arthritis or B-cell lymphoma. Also, 
immunological safety was expected to be more in healthy 
subjects compared to those with pre-existing disease. In 
addition, healthy subjects would not only exclude effects 
of other medications administered to diseased patients, 
but also exclude the effects of functional activation or 
dysfunctionalization of T cells as a result of prior diseased 
condition.[2]
DOSE CALCULATION
Since TGN1412 showed specificity toward CD28 
receptor expressed on human and non-human primate 
T cells, safe dose calculated from preclinical studies in 
non-human primate model was considered of suitable 
relevance for calculation of first in human dose. Various 
tests for expected pharmacological activity of TGN1412 
and unexpected toxicological effects of TGN1412 were 
conducted in non-human primates cynomolgus and rhesus 
monkeys. These tests demonstrated a dose of 50 mg/kg 
administered for four consecutive weeks to be safe [21] On 
the basis of the repeat dose toxicity studies in cynomolgus 
monkeys, no observed adverse effectt level (NOAEL) was 
considered to be 50 mg/kg per week for not less than 
four consecutive weeks. Considering FDA guidelines, 
“Minimal Anticipated Biological Effect Level” (MABEL) 
approach and the Safety Criteria for the safe first dose, 
a dose of 0.1 mg/kg was decided to be administered to 
healthy volunteers in a double-blind randomized placebo-
controlled phase I clinical trial conducted.
THE FIRST DOSE DISASTER
After collection of this large amount of preclinical data, 
when TGN1412 was administered to six healthy human 
volunteers in phase 1 clinical trial conducted by Paraxel for 
TeGenero at Northwick hospital in London, UK, minutes 
after the first infusion of humanized CD28 superagonist 
TGN1412, all patients started suffering from severe 
adverse reaction resulting from rapid release of cytokines 
by activated T cells.[7] Table 1 lists some of the important 
lessons from TGN1412 trial failure.
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After this unexpected outcome of the trial United 
Kingdom’s Medicines and Healthcare Products Regulatory 
Agency (MHRA) initiated an investigation on the trial 
procedures and ethics. They did not find any flaw in trial 
procedure or in manufacture of drug. They mentioned 
that the severe reactions were as a result of unexpected 
biological effect of the drug.[9] Deficiencies they found in 
the drug trail were inadequate maintenance medical records, 
physician with inappropriate qualification, inadequacy in 
ensuring insurance protection of the sponsor, and failure 
in arranging early medical coverage.[10] In addition, there 
was no citation mentioned in the investigation brochure 
supporting the 100% homology of CD28 receptor between 
primate species used for preclinical trial and humans. Later, 
it was reviewed by Hansen and Leslie[11] that differences 
of up to 4% existed in the amino-acid sequences of the 
C″D loop of CD28 receptor in rhesus and cynomolgus 
with that of humans. This raises doubts on whether 
trial met the criteria on scientific validity of preclinical 
data.  [10] Later, British Journal of  Medicine and other journals 
requested for a more critical trial inquiry independent of 
the authorities who approved the trial. Toward this end, 
expert scientific group under Professor Gordon Duff 
was formed which further investigated the biological and 
ethical concerns which may have resulted in the disastrous 
aftermath.[12] Just after few minutes of drug infusion, all 
six human volunteers started suffering severe cytokine 
release syndrome leading to sever inflammation.[13] Similar 
effects were observed in small number of patients treated 
with rituximab, muromonab-CD3, and alemtuzumab 
antibodies.[13] Even the investigation brochure had in its 
text mentioned caution about possibility of cytokine release 
syndrome. Despite of knowing these facts infusion of 
TGN1412 given to all six volunteers within a short span 
of time was a serious concern in conduct of the trial. 
Moreover, when the last volunteer was to be infused, the 
first volunteer had already started showing adverse effects. 
Despite of this observation, sixth volunteer was still 
infused with the drug.  [4] Moreover, the place where trial was 
conducted was not a hospital but a privately leased unit by 
Paraxel, which delayed the quick diagnosis and treatment of 
affected volunteers.[4,10] In addition, the preclinical test did 
not include a test for allergy. This was important because 
CD28 is also expressed by the cells responsible for allergy 
and the fact that the adverse reactions were immediate, 
relates to the release of preformed cytokines in granules 
of allergy-mediating immune cells. Inclusion of an allergy 
test in preclinical studies might have predicted the massive 
cytokine release.[14]
In an another clinical trial conducted by National Institute 
of Health for the drug Fialuridine, a thymidine analog 
having antiviral activity against Hepatitis B virus showed 
adverse reactions in phase 2 clinical trials leading to death 
of five human volunteers due to severe hepatic toxicity and 
lactic acidosis.[15] Before conducting human trials, Fialuridine 
was tested on different animals including mice, rat, dog, 
monkeys, and woodchucks. These studies demonstrated 
that doses hundred times higher than that administered 
to humans did not induce any toxic reactions. Moreover, 
animal models showed bone marrow and heart toxicity with 
no signs of mitochondrial injury.[16] None of the preclinical 
toxicity studies on laboratory animals could predict the 
toxic outcomes observed in phase II studies. Even a pilot 
study on 43 patients treated for 2 and 4 weeks duration with 
Fialuridine did not reveal any signs of hepatic toxicity on 
initial examination.[17] During 13th week of phase II studies, 
one of the patients suddenly developed hepatic toxicity 
and lactic acidosis. At this point, trial was stopped for all 
other patients. Even after discontinuation of Fialuridine 
Table 1: Summary of learning points from the TGN1412 phase I study
TGN1412 study problem Detail Learning Point
Interpretation of preclinical (primate) studies Low-level cytokine release in primate studies should 
have promoted more caution
Minor but potentially important effects in preclinical 
studies should raise caution in crossing the species 
barrier
Use of human in vitro studies Insufficient in-vitro human studies were performed In vitro studies on human material as close as 
possible to the target tissue can be important.
Choice of starting dose Subtle difference between primate and human target 
ligand may explain marked difference in potency 
– the calculation of an initial dose based on a 
fraction of predicted ‘no adverse effect level’ proved 
dangerously wrong
Prediction of risk and dose range from animal studies 
may prove unreliable: extra caution with wider 
margins of safety are required with ‘potentially risky 
modes of action’
Dosing interval between subjects No ‘proper interval’ allowing for the observation of 
possible side effects was left between the dosing of 
one subject and the next
In fisrt-in-man studies, investigators should expect 
the unexpected
Preparation for adverse events Preparation for possible adverse events (cytokine 
storm) was inadequate – investigators did not expect 
it, recognize it or treat early.
Where there is a known theoretical risk, investigators 
should plan for its potential occurrence
Adapted from Dayan and Wraith[8]
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administration, seven other patients showed signs of severe 
hepatic toxicity five of which could not survive and other 
two could survive only after liver transplantation.[17] It was 
reported by Richardson et al.[18] that Fialuridine accumulates 
in genomic DNA in liver and also other tissues after chronic 
oral drug administration. Accumulation of Fialuridine in 
genomic DNA specifically in liver may be responsible for its 
toxic effects due to production of defective mitochondrial 
DNA resulting in high levels of lactic acid and deposition 
of fat in mitochondrial microvesicles.[19] Fialuridine can 
get incorporated into cellular and mitochondrial nacent 
DNA which may result in inhibition of DNA synthesis or 
synthesis of abnormal DNA.[17,18] This unexpected tragedy 
has focused attention of researchers on possibility of a new 
type of delayed toxic effect due to mitochondrial injury.[19]
Later after these disastrous trial outcomes, woodchucks 
with Hepatitis B virus infection were used for evaluation of 
hepatotoxicity. The main aim of this study was to develop 
a suitable animal model, which can predict clinical toxicity 
in humans by preclinical studies prior to use of nucleoside 
analogs in clinical trials. Initial 8-week treatment showed 
lowering in serum levels of Hepatitis B virus but later after 
from 12th week onward woodchucks began to loose weight 
and began to show mitochondrial injury.[20] Since no such 
chronic administration studies were carried out prior to 
Fialuridine clinical trial, observed chronic toxicity effects 
remained unpredicted by preclinical studies. Now for all 
preclinical studies involving nucleoside analogs for HBV 
treatment, a woodchuck model is used for evaluation of 
mitochondrial toxicity.[16]
CONCLUSION 
Drugs showing safety and efficacy in preclinical animal 
models may show very different pharmacological 
properties when administered to humans. Development 
of proper preclinical models which can efficiently predict 
drug behavior in humans is very essential prior to testing 
a drug in a human subject. First in man, human trials 
of potent biological molecules should include initial 
testing on very less number of human volunteers before 
administration of drug to a greater number of human 
volunteers. The above-mentioned incidents especially the 
TeGenero incident was an alarming call for the researchers 
and also for the trial approving regulatory authorities on 
toxicity-related unpredictability of new drugs in human 
subjects especially for biological with a novel mechanism 
of action like TGN1412. Though there is always a risk 
involved with clinical trials, these risks can be potentially 
reduced if more scientific research toward development of 
animal models closely mimicking drug behavior in humans 
can be developed.
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